BTIG upgraded Outlook Therapeutics to Buy from Neutral with a $50 price target after increasing the firm’s view of the probability of success for ONS-5010 to 90% from 35% and lowering its discount rate. Given several highly enabling milestones achieved by the company in the year-to-date, the path to BLA resubmission for ONS-5010 in wet AMD “looks clear to us,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OTLK:
- Outlook Therapeutics Grants Stock Options to Top Executives
- Outlook Therapeutics files to sell 21.43M shares of common stock for holders
- Outlook Therapeutics Inc trading resumes
- Outlook Therapeutics Inc trading halted, volatility trading pause
- Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
